Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.

Vivani Medical, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

ALAMEDA, CALIF., JULY 14, 2026 (GLOBE NEWSWIRE) -- VIVANI MEDICAL, INC. (NASDAQ: VANI) (THE COMPANY OR VIVANI), AN INNOVATIVE, BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL, MINIATURE, GLP-1 DRUG IMPLANTS WITH ONCE- OR TWICE-YEARLY ADMINISTRATION, TODAY ANNOUNCED THAT IT WILL PRESENT AT THE EMERGING GROWTH CONFERENCE ON JULY 15, 2026.

VIVANI MEDICAL TO PRESENT AT THE EMERGING GROWTH CONFERENCE ON JULY 15, 2026

ALAMEDA, CALIF., JULY 07, 2026 (GLOBE NEWSWIRE) -- VIVANI MEDICAL, INC. (NASDAQ: VANI) (VIVANI OR THE COMPANY), AN INNOVATIVE, BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL, ULTRA LONG-ACTING DRUG IMPLANTS, TODAY ANNOUNCED THE SIGNING OF A NEW AGREEMENT WITH NOVO NORDISK TO ENABLE NOVO NORDISK TO EVALUATE NPM-139, THE COMPANY'S SEMAGLUTIDE DRUG IMPLANT.

VIVANI MEDICAL ENTERS INTO AGREEMENT WITH NOVO NORDISK TO EVALUATE NPM-139, A MINIATURE, ULTRA LONG-ACTING SEMAGLUTIDE IMPLANT FOR CHRONIC WEIGHT MANAGEMENT

VIVANI PROPOSES TO MERGE CORTIGENT, INC. WITH A WHOLLY OWNED SUBSIDIARY OF CLEARONE, INC. (NASDAQ: CLRO), AND CHANGE THE LISTED COMPANY'S NAME AND TICKER TO CORTIGENT HOLDINGS, INC. (D/B/A CORTIGENT) AND CRGT

VIVANI ANNOUNCES ENTRY INTO MERGER AGREEMENT BETWEEN WHOLLY OWNED SUBSIDIARY CORTIGENT, INC. AND NASDAQ-LISTED CLEARONE, INC.

SALT LAKE CITY--(BUSINESS WIRE)--CLEARONE, INC. (NASDAQ: CLRO) (CLEARONE) ANNOUNCED TODAY THAT IT HAS ENTERED INTO A DEFINITIVE AGREEMENT AND PLAN OF MERGER (THE AGREEMENT) AMONG ITS WHOLLY-OWNED SUBSIDIARY (MERGERSUB), VIVANI MEDICAL, INC. (NASDAQ: VANI; VIVANI), AND CORTIGENT, INC. (CORTIGENT), A WHOLLY-OWNED SUBSIDIARY OF VIVANI, PURSUANT TO WHICH CORTIGENT WILL BECOME A WHOLLY-OWNED SUBSIDIARY OF CLEARONE (THE TRANSACTION) UPON CONSUMMATION. IN CONNECTION WITH THE TRANSACTION, C.

CLEARONE ANNOUNCES ENTRY INTO MERGER AGREEMENT WITH CORTIGENT, INC., A WHOLLY-OWNED SUBSIDIARY OF VIVANI MEDICAL

ALAMEDA, CALIF., JUNE 26, 2026 (GLOBE NEWSWIRE) -- VIVANI MEDICAL, INC. (NASDAQ: VANI) (VIVANI OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MINIATURE, ULTRA LONG-ACTING DRUG IMPLANTS, TODAY ANNOUNCED THE APPOINTMENT OF AUGUST MORETTI TO ITS BOARD OF DIRECTORS. CONCURRENT WITH THIS APPOINTMENT, THE COMPANY ANNOUNCED THE RETIREMENT OF DR. DEAN BAKER FROM THE BOARD.

VIVANI MEDICAL ANNOUNCES APPOINTMENT OF AUGUST J. MORETTI TO BOARD OF DIRECTORS AND RETIREMENT OF DR. DEAN BAKER

ALAMEDA, CALIF., JUNE 25, 2026 (GLOBE NEWSWIRE) -- VIVANI MEDICAL, INC. (NASDAQ: VANI) (VIVANI OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MINIATURE, ULTRA LONG-ACTING DRUG IMPLANTS, ANNOUNCED TODAY THAT IT HAS RECEIVED APPROVAL FROM BELLBERRY, A HUMAN RESEARCH ETHICS COMMITTEE (HREC) IN AUSTRALIA TO INITIATE SLIM-1, A PHASE 1 CLINICAL TRIAL OF NPM-139, A SEMAGLUTIDE IMPLANT.

VIVANI MEDICAL RECEIVES REGULATORY APPROVAL FOR THE INITIATION OF SLIM-1, A PHASE 1 CLINICAL TRIAL OF NPM-139 SEMAGLUTIDE IMPLANT IN OBESITY AND CHRONIC WEIGHT MANAGEMENT

ALAMEDA, CALIF., JUNE 22, 2026 (GLOBE NEWSWIRE) -- VIVANI MEDICAL, INC. ( NASDAQ: VANI ) (VIVANI OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MINIATURE, ULTRA LONG-ACTING DRUG IMPLANTS, ANNOUNCED TODAY THAT CEO ADAM MENDELSOHN, PH.D., WILL PRESENT A COMPANY OVERVIEW AND HOST INVESTOR AND PARTNER MEETINGS AT THE 2026 BIO INTERNATIONAL CONVENTION TAKING PLACE THIS WEEK IN SAN DIEGO, CALIFORNIA.

VIVANI MEDICAL CEO ADAM MENDELSOHN TO PRESENT AT THE 2026 BIO INTERNATIONAL CONVENTION

INITIATION OF SLIM-1 CLINICAL TRIAL, A PHASE 1 STUDY OF NPM-139, A SEMAGLUTIDE IMPLANT UNDER DEVELOPMENT FOR CHRONIC WEIGHT MANAGEMENT, ON TRACK FOR MID-YEAR 2026 $28 MILLION IN CASH, CASH EQUIVALENTS, RESTRICTED CASH AND CAPITAL COMMITMENTS EXPECTED TO FUND CURRENT OPERATING PLAN THROUGH THE FIRST HALF OF 2027 ALAMEDA, CALIF., MAY 13, 2026 (GLOBE NEWSWIRE) -- VIVANI MEDICAL, INC. (NASDAQ: VANI) (VIVANI OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MINIATURE, ULTRA LONG-ACTING SUBDERMAL DRUG IMPLANTS UTILIZING ITS PROPRIETARY NANOPORTAL TECHNOLOGY, TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026, AND PROVIDED A BUSINESS UPDATE.

VIVANI MEDICAL REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

SUCCESSFUL COMPLETION OF FIRST-IN-HUMAN STUDY LIBERATE-1 PAIRED WITH PRECLINICAL PROOF OF CONCEPT DATA FOR A SEMAGLUTIDE IMPLANT ADVANCE NPM-139, MINIATURE, ULTRA LONG-ACTING SEMAGLUTIDE IMPLANT UNDER DEVELOPMENT FOR CHRONIC WEIGHT MANAGEMENT TOWARD A PHASE 1 CLINICAL STUDY WITH RESULTS ANTICIPATED BY THE END OF 2026.

VIVANI MEDICAL REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

CORTIGENT IS A LEADING DEVELOPER OF BRAIN IMPLANT DEVICES BASED ON PRECISION NEUROSTIMULATION TECHNOLOGY CORTIGENT IS THE ONLY COMPANY TO HAVE OBTAINED FDA APPROVAL OF A DEVICE PROVIDING ARTIFICIAL VISION FOR THE PROFOUNDLY BLIND THE COMPANY IS ALSO DEVELOPING A NEW MEDICAL DEVICE AIMED AT IMPROVING RECOVERY OF ARM AND HAND MOTION IN PATIENTS WITH PARALYSIS DUE TO STROKE ALAMEDA, CALIF., JAN. 29, 2026 (GLOBE NEWSWIRE) -- VIVANI MEDICAL, INC. (NASDAQ: VANI) (VIVANI OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MINIATURE, ULTRA LONG-ACTING DRUG IMPLANTS, ANNOUNCED TODAY THAT CORTIGENT, INC. (CORTIGENT), ITS WHOLLY-OWNED SUBSIDIARY DEVELOPING BRAIN IMPLANT DEVICES, PRESENTED THE RESULTS OF A 6-YEAR EARLY FEASIBILITY STUDY OF THE ORION VISUAL CORTICAL PROSTHESIS SYSTEM UNDER DEVELOPMENT TO DELIVER MEANINGFUL VISUAL PERCEPTION TO BLIND PERSONS AT THE NORTH AMERICAN NEUROMODULATION SOCIETY (NANS) ANNUAL MEETING.

Vivani Medical, Inc.

VANI

Price

Financial Reports

No items found.

Press Releases

Vivani Medical, Inc.

VANI.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

VANI